secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2023-05-26T23:59:59+00:00
Accession:  0001725160-23-000119
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis announces positive Phase 1b data for azenosertib; plans Phase 3 trial in Cyclin E1+ ovarian cancer
--------------------------------------------------------------------------------

- Azenosertib + paclitaxel achieved 50% ORR (7.4 months mPFS) in platinum-resistant ovarian cancer.
- Cyclin E1+ tumors showed 40% ORR vs 8.3% in Cyclin E1- (HR=0.37; p=0.0078).
- Well tolerated; Grade ≥3 AEs: thrombocytopenia (27.5%), neutropenia (25.5%), anemia (15.7%), fatigue (9.8%).
- Phase 3 study of azenosertib in combination with chemotherapy in Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000119/0001725160-23-000119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000119/zntl-20230525.htm
  HTML page:      https://secwatch.observer/filing/0001725160-23-000119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer